Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics Inc.

Sera Prognostics ( ($SERA) ) just unveiled an update. On June 4, 2026, Sera Prognostics, Inc. held its 2026 Annual Meeting of Stockholders via live...

Sera Prognostics Holds 2026 Annual Stockholders Meeting

The latest update is out from Sera Prognostics ( ($SERA) ). On May 26, 2026, Sera Prognostics director Jeffrey T. Elliott notified the company he w...

Market Cap	$139.69M	P/E Ratio	N/A
52W High	$4.09	52W Low	$1.56
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	22.3%	52W Position	7.5%
Overall Score	51	Value Score	60
Quality Score	50	Technical Score	45

EPS Current Est	$-0.58	EPS Next Est	$-0.51
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SERA	$1.75	-7.41%	87.46K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SERA	$1.75	-7.4%	87.46K
3
4
5
6

SERA

SERA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Sera Prognostics Inc. Data in Excel

Get Sera Prognostics Inc. Data in Excel